久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Novartis to team up with Chinese tech giants

By Liu Zhihua | China Daily | Updated: 2019-04-02 10:49
Share
Share - WeChat
Employees analyze data at a high-tech command center on the Novartis AG campus in Basel, Switzerland. [Photo/Agencies]

Swiss pharmaceutical giant Novartis AG is looking to further tap into China's healthcare market by bringing more innovative drugs, while enhancing collaborations with local biotech and technology companies to further digital transformation of healthcare, a top company official said.

Vas Narasimhan, CEO of Novartis, said he expects China to "become one of the top three markets for Novartis by sales in the coming years". The company is ready to bring more than 10 innovative medicines to China over the coming years, thanks to the country's commitment to further reform and opening-up, and its ongoing efforts to speed up new drug approvals, he said.

"Over the last 20 years China has been able to evolve from a country that was primarily focused on generic medicines and vaccines to now being able to bring the latest innovations," he said.

"China's strategy of opening-up to our industry and opening-up to innovation will benefit Chinese patients and also enable companies like us to keep investing in China."

In recent years, especially from five years ago, Chinese regulators have been streamlining and accelerating new drug approvals, with efforts such as increasing the head count of staff for new drug reviews and speeding up approvals for drugs in urgent clinical need or for treating rare diseases.

At the recently closed China Development Forum 2019, Wang Ping, director general of the department of drug registration under the National Medical Products Administration, revealed that China approved 48 new medicines in 2018, and reduced the approval period by a year.

"Now China's regulatory timelines are at the same level of what we see in the United States or in Europe," Narasimhan said, adding that Novartis got nine new medicines approved in China in the past two years alone, at a pace faster than ever.

Novartis, which spends more than $9 billion on research and development every year, runs an innovation hub in Shanghai, with an investment of $1 billion. The campus, with more than 700 scientists focusing mainly on research of cancer and liver diseases prevalent in Asia and China, is now playing an increasingly important role in new drug development.

"I think our investment in innovation is bringing a number of new launches to China in our portfolio over the next three years," Narasimhan said.

China is now the world's second-largest market for pharmaceuticals, second only to the United States. Iqvia, a healthcare information company, earlier said China's pharmaceutical market will reach $145 billion to $175 billion by 2022, compared with $122.6 billion in 2017.

The CEO said Novartis is also engaging with Chinese regulators and local partners to bring cell and gene therapies to China, which have been heralded as a breakthrough in treating many intractable illnesses.

Last September, Novartis announced a deal with Shanghai-based biotech company Cellular Biomedicine Group, for manufacturing Kymriah, a CAR-T cell therapy, or chimeric antigen receptor cell therapy, treatment for cancer. Kymriah has already been approved in Europe, Canada, and Australia and Novartis is looking to bring the same to China soon.

"I believe our collaboration with Chinese partners can help China become the leader among the emerging markets in bringing cell and gene therapies to countries," said Narasimhan, who presented a policy paper at the CDF 2019 with a wide range of recommendations to the Chinese government, including the regulatory framework, requirements for the research and applications, as well as the establishment of flexible payment mechanisms and alternative funding models.

Narasimhan said that digital technologies have been a major driver fueling the company's business expansion in China.

In addition to 40 biotech companies that Novartis currently has partnerships with, the company is also planning partnerships with technology companies in China.

On March 22, the company signed a global strategic partnership deal with Chinese tech giant Tencent to apply integrated big data, artificial intelligence and social media technologies for better patient outcomes on chronic diseases.

The CEO took the helm at Novartis last year and has envisioned a focused medicines company that's powered by data sciences and digital technologies and has launched a number of initiatives to transform Novartis while reshaping the healthcare sector using digital technologies.

"We began the partnership with Tencent in cardiovascular diseases to help identify patients who need care and help patients stay on the right medicine," said Narasimhan.

"Now we are expanding the collaboration to cover all the chronic diseases. This is one of our most advanced partnerships in the world and a model for the rest. Our strategy in China is about growth, innovation, and digital technologies."

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 中国国产一国产一级毛片视频 | 五月激情丁香婷婷综合第九 | 成人免费a视频 | 日本欧美不卡一区二区三区在线 | 久久韩国| 97免费视频在线观看 | 免费一级a毛片 | 欧美一级特黄特黄做受 | 亚洲精品久久一区二区无卡 | 亚洲精品第一第二区 | 久久亚洲精品中文字幕第一区 | 成人永久免费视频 | 亚洲精品一区二区三区四区 | 日韩综合网站 | 久草福利在线观看 | 欧美精品午夜毛片免费看 | 美女视频黄色免费 | 青青久草 | 好爽~好硬~好紧~蜜芽 | 自拍视频精品 | 狠狠久久综合 | 免费99热在线观看 | 国产九区 | 性生大片一级毛片免费观看 | 亚洲日韩中文字幕 | 久久黄色一级视频 | 日韩欧美视频一区二区在线观看 | 亚洲国产高清在线精品一区 | 九九亚洲精品自拍 | 最新更新国内自拍视频 | 特级毛片8级毛片免费观看 特级毛片免费观看视频 | 亚洲精品资源在线 | 日本三级香港三级人妇99 | 办公室紧身裙丝袜av在线 | 久久成人免费 | 玖玖精品国产 | 久久草在线视频 | 日韩三级观看 | 国产一区二区三区免费在线观看 | 国产日产久久高清欧美一区 | 男人的天堂在线观看免费 |